Doxorubicin (Synonyms: Hydroxydaunorubicin) |
Catalog No.GC16994 |
Doxorubicin(DOX), also known as adriamycin, is a compound of the anthracycline class that has the broadest spectrum of activity[1].
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 23214-92-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
Human lung carcinoma (A549) cell lines |
Preparation Method |
About 1×105 A549 cells/well were plated into 12-well culture dishes and incubated for 24h. After 24h, doxorubicin, as well as conjugates of doxorubicin at a concentration equivalent to 2µg/ml of doxorubicin was added and incubated for time periods of 4 and 12h. |
Reaction Conditions |
2µg/ml |
Applications |
The uptake of the free doxorubicin and conjugates into the A549 cells increased with time. The fluorescent images of cells treated with free doxorubicin and polymannose(PM)-doxorubicin showed better uptake, while the sodium alginate(SA)-doxorubicin showed significantly lesser uptake after 4 and 12h exposure. |
Animal experiment [2]: | |
Animal models |
BALB/c mice (5-6 weeks, female) and BALB/c athymic nude mice (nu/nu, 5-6 weeks, male) |
Preparation Method |
For in vivo tumor implantation, C26 cells at 5×105 cells in 30µL Minimum Essential Medium (MEM) and MIA PaCa-2 cells at 2×106cells in 50µL 10:90 v/v MEM: Matrigel matrix were inoculated in the right flank of normal and athymic nude BALB/c mice, respectively. Tumor cells were allowed to grow until the tumor volume-reached 75-100mm3 for C26 tumors and 100-125mm3 for MIA PaCa-2 tumors. Tumor-bearing mice were then treated with a single i.v. injection of albumin-binding domain-doxorubicin (ABD-DoX) at 10 and 20mg doxorubicin equiv. kg-1 BW, AlDoxorubicin at 20mg doxorubicin equiv. kg-1 BW, and free doxorubicin at 10mg·kg-1 BW. |
Dosage form |
ABD-Doxorubicin at 10 and 20mg doxorubicin equiv. kg-1 BW, AlDoxorubicin at 20mg doxorubicin equiv. kg-1 BW, and free doxorubicin at 10mg kg-1 BW. |
Applications |
ABD-Doxorubicin has superior therapeutic efficacy to AlDoxorubicin in the syngeneic C26 colon carcinoma model in BALB/c mice and in the MIA PaCa-2 pancreatic adenocarcinoma xenograft model in nude mice, and that both formulations are superior to free Doxorubicin. |
References: [1]. Francis AP, Jayakrishnan A. Conjugating doxorubicin to polymannose: a new strategy for target specific delivery to lung cancer cells. J Biomater Sci Polym Ed. 2019;30(16):1471-1488. [2]. Yousefpour P, Ahn L, et al. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin. Small. 2019;15(12):e1804452. |
Doxorubicin(DOX), also known as adriamycin, is a compound of the anthracycline class that has the broadest spectrum of activity[1]. Doxorubicin inhibits topoisomerase Ⅱ and topoisomerase Ⅰ with IC50 of 2.67μM and 0.8μM, respectively[2,3]. It is widely used for the treatment of various solid tumors via interacting with deoxyribonucleic acid, but it is limited in the clinical application due to severe side effect[4]
Doxorubicin can be loaded into liposomes by transmembrane pH gradient method to get high encapsulation efficiency with high drug/lipid ratio. Liposomal doxorubicin is a successful clinical formulation, and also a perfect model drug system for cancer-therapy research[5]. A considerable amount of doxorubicin can accumulate in human placental tissue. Both doxorubicin and its pH-sensitive liposomal formulation, L-Doxorubicin, are efficiently internalized by human trophoblastic BeWo cells and that doxorubicin accumulates in placental tissue so that decrease the exposure of fetal[6]
Doxorubicin combines with cobimetinib at sublethal dose completely arrested osteosarcoma growth. Targeted MEK inhibition by cobimetinib enhances doxorubicin’s efficacy in osteosarcoma models[7]. Doxorubicin is frequently used as an adjuvant chemotherapeutic agent for breast cancer. Silk films loaded with doxorubicin provide locoregional control of human breast cancer in vivo. By manipulating silk crystallinity or β-sheet content, the doxorubicin release rate could be controlled. Both soluble and stabilised silk films loaded with doxorubicin had a significantly greater primary tumour response than the equivalent dose of doxorubicin administered intravenously in the absence of the silk film carrier. The future use of this approach for localised chemotherapy is promising[8]
Cas No. | 23214-92-8 | SDF | |
Synonyms | Hydroxydaunorubicin | ||
Chemical Name | (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione | ||
Canonical SMILES | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O | ||
Formula | C27H29NO11 | M.Wt | 543.52 |
Solubility | 20mg/mL in Water(Need ultrasonic); 20mg/mL in DMSO(Need ultrasonic) | Storage | Store at -20°C, protect from light |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.8399 mL | 9.1993 mL | 18.3986 mL |
5 mM | 0.368 mL | 1.8399 mL | 3.6797 mL |
10 mM | 0.184 mL | 0.9199 mL | 1.8399 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *